Dr. Hailin Zhang 张海林
Chief Physician
Department of Head and Neck Surgery, Hunan Cancer Hospital, Changsha
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment and reconstruction for head and neck cancers, including oral cavity, thyroid, nasal, laryngeal, and salivary gland tumors. Expertise in open and endoscopic thyroid surgery, free flap reconstruction, and digital surgical techniques for jaw reconstruction.
Dr. Zhang is Deputy Director of the First Department of Head and Neck Surgery and holds a medical doctorate. The doctor has extensive experience in radical surgery and defect repair for head and neck malignancies, particularly in thyroid cancer and oral cancer reconstruction using free flaps and digital surgical technologies.
Professional roles
- Member and Secretary, Tumor Plastic Surgery Professional Committee, China Anti-Cancer Association
- Member, Head and Neck Tumor Professional Committee, China Anti-Cancer Association
- Member, Tumor Plastic and Functional Surgery Committee, China Medical Promotion Association
- Member and Secretary, Head and Neck Group, Oncology Professional Committee, Hunan Medical Association
Name order: in Chinese the family name comes first (Zhang Hailin). Papers usually list the name as Hailin Zhang or Zhang H.
Selected publications
12 papers on PubMed matched by name and affiliation; 3 as first or senior author since 2016. Most recent first- or senior-author papers:
- Mol Cancer, 2025 (senior author): Neoadjuvant immunotherapy in squamous cell carcinoma of the head and neck: current evidence and future perspectives. PubMed 41214710
- Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2022 (senior author): [Nasal endoscopy assisting combined with transoral approach for resection of carcinoma of the palate invading nasal cavity and sinuses]. PubMed 35193341
- Mol Carcinog, 2021 (senior author): The LncRNA FGD5-AS1/miR-497-5p axis regulates septin 2 (SEPT2) to accelerate cancer progression and increase cisplatin-resistance in laryngeal squamous cell carcinoma. PubMed 34003510
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion